Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
- Felip, E.
- Cho, B.C.
- Gutiérrez, V.
- Alip, A.
- Besse, B.
- Lu, S.
- Spira, A.I.
- Girard, N.
- Califano, R.
- Gadgeel, S.M.
- Yang, J.C.-H.
- Yamamoto, S.
- Azuma, K.
- Kim, Y.J.
- Lee, K.-H.
- Danchaivijitr, P.
- Ferreira, C.G.
- Cheng, Y.
- Sendur, M.A.N.
- Chang, G.-C.
- Wang, C.-C.
- Prabhash, K.
- Shinno, Y.
- Stroyakovskiy, D.
- Paz-Ares, L.
- Rodriguez-Cid, J.R.
- Martin, C.
- Campelo, M.R.G.
- Hayashi, H.
- Nguyen, D.
- Tomasini, P.
- Gottfried, M.
- Dooms, C.
- Passaro, A.
- Schuler, M.
- Gelatti, A.C.Z.
- Owen, S.
- Perdrizet, K.
- Ou, S.-H.I.
- Curtin, J.C.
- Zhang, J.
- Gormley, M.
- Sun, T.
- Panchal, A.
- Ennis, M.
- Fennema, E.
- Daksh, M.
- Sethi, S.
- Bauml, J.M.
- Lee, S.-H.
- Show all authors +
ISSN: 1569-8041, 0923-7534
Year of publication: 2024
Volume: 35
Issue: 9
Pages: 805-816
Type: Article